3-Year Follow-up of Chemotherapy Following Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (CRPC) Patients (Pts) With Symptomatic Bone Metastases (Mets) From ALSYMPCA

被引：0
|
作者：
Koenig, E. [1 ]
Sartor, O. [2 ]
Coleman, R. E. [3 ]
Nilsson, S. [4 ]
Voyelzang, N. [5 ]
Staudacher, K. [6 ]
Thuresson, M. [7 ]
Parker, C. [8 ,9 ]
机构：
[1] Outpatient Clin Urol, Berlin, Germany
[2] Tulane Canc Ctr, New Orleans, LA USA
[3] Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[6] Bayer AS, Oslo, Norway
[7] Statisticon AB, Uppsala, Sweden
[8] Royal Marsden NHS Fdn Trust, Sutton, Grossbritannien, England
[9] Inst Canc Res, Sutton, Grossbritannien, England
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0099
引用
收藏
页码：86 / 86
页数：1
相关论文
共 50 条
  • [1] 3-year follow-up of chemotherapy following radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases (Mets) from ALSYMPCA
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N. J.
    Staudacher, K.
    Thuresson, M.
    Parker, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S477 - S477
  • [2] 3-year safety follow-up of Radium-223 Dichloride (Ra-223) in patients (Pts) with Castration-Resistant Prostate Cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Kramer, M. W.
    Kuczyk, M. A.
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Coleman, R. E.
    Fang, F.
    Skjorestad, I
    Nilsson, S.
    Oncology Research and Treatment, 2015, 38 : 266 - 266
  • [3] 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Amadori, D.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Vogelzang, N. J.
    Sartor, A.
    Coleman, R. E.
    Govi, S.
    Fang, F.
    Skjorestad, I.
    Nilsson, S.
    Parker, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 55 - 55
  • [4] 3-year safety yellow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Parker, Chris
    Vogelzang, Nicholas J.
    Salter, A. Oliver
    Coleman, Robert E.
    Fang, Fang
    Skjorestad, Irene
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [5] 3-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
    Parker, Chris
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Coleman, Robert E.
    Skjorestad, Irene
    Fang, Fang
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Radium-223 dichloride (Ra-223) hematologic and 1.5-year posttreatment safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from ALSYMPCA
    Conti, Peter
    Michalski, Jeff
    Skjorestad, Irene
    Wahba, Mona
    Nilsson, Sten
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [7] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [8] 1.5-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study
    Kuczyk, M.
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Bottomley, D.
    Coleman, R.
    Skjorestad, I.
    Whaba, M.
    Nilsson, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 178 - 178
  • [9] 1.5-YEAR POSTTREATMENT FOLLOW-UP OF RADIUM-223 DICHLORIDE (RA-223) SAFETY IN PATIENTS (PTS) WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATIC BONE METASTASES FROM ALSYMPCA: CHARACTERIZATION OF HEMATOLOGIC SAFETY PROFILES
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Bottomley, D.
    Coleman, R. E.
    Skjorestad, I.
    Aksnes, A.
    Wahba, M.
    Nilsson, S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [10] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
    Paganelli, G.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Michalski, J. M.
    O'Sullivan, J. M.
    Parker, C.
    Garcia-Vargas, J. E.
    Sartor, A.
    Finkelstein, S. E.
    ANNALS OF ONCOLOGY, 2015, 26 : 62 - 62
12345